Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has said that Vasolan tablets 40mg has received approval in Japan for the additional indications of the treatment of atrial fibrillation or flutter and paroxysmal supraventricular tachycardia.
Subscribe to our email newsletter
The additional indications approved by agency for the oral form of Vasolan will provide a wider range of treatment options for patients who are suffering from tachyarrhythmia.
This approval, together with company’s other related products including Tambocor for the indication of tachyarrhythmia and Warfarin as an anticoagulant, will enable Eisai to make further contributions to patients by offering treatment options for managing atrial fibrillation.